These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 19124479)

  • 21. Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer.
    Aharinejad S; Salama M; Paulus P; Zins K; Berger A; Singer CF
    Endocr Relat Cancer; 2013 Dec; 20(6):777-83. PubMed ID: 24016870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
    Baglietto L; Torrisi R; Arena G; Tosetti F; Gonzaga AG; Pasquetti W; Robertson C; Decensi A
    Cancer Detect Prev; 2000; 24(4):369-75. PubMed ID: 11059568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
    Tworoger SS; Eliassen AH; Sluss P; Hankinson SE
    J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.
    Schierbeck LL; Rejnmark L; Tofteng CL; Stilgren L; Eiken P; Mosekilde L; Køber L; Jensen JE
    BMJ; 2012 Oct; 345():e6409. PubMed ID: 23048011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
    Formelli F; Clerici M; Campa T; Di Mauro MG; Magni A; Mascotti G; Moglia D; De Palo G; Costa A; Veronesi U
    J Clin Oncol; 1993 Oct; 11(10):2036-42. PubMed ID: 8410127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma carotenoids, retinol, and tocopherols and postmenopausal breast cancer risk in the Multiethnic Cohort Study: a nested case-control study.
    Epplein M; Shvetsov YB; Wilkens LR; Franke AA; Cooney RV; Le Marchand L; Henderson BE; Kolonel LN; Goodman MT
    Breast Cancer Res; 2009; 11(4):R49. PubMed ID: 19619335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
    J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers.
    Jaskulski S; Jung AY; Behrens S; Johnson T; Kaaks R; Thöne K; Flesch-Janys D; Sookthai D; Chang-Claude J
    Int J Cancer; 2018 Dec; 143(11):2698-2708. PubMed ID: 29974464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
    Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro MG; Costa A; Marubini E; Sporn MB; De Palo G
    Ann Oncol; 2006 Jul; 17(7):1065-71. PubMed ID: 16675486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum vitamin A level in breast cancer patients.
    Hou MF; Tsai LY; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Chen HM; Wang JY
    Kaohsiung J Med Sci; 1998 Nov; 14(11):673-8. PubMed ID: 9838762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-Response Relationship between Serum Retinol Levels and Survival in Patients with Colorectal Cancer: Results from the DACHS Study.
    Maalmi H; Walter V; Jansen L; Owen RW; Ulrich A; Schöttker B; Chang-Claude J; Hoffmeister M; Brenner H
    Nutrients; 2018 Apr; 10(4):. PubMed ID: 29671819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.
    Mariani L; Formelli F; De Palo G; Manzari A; Camerini T; Campa T; Di Mauro MG; Crippa A; Delle Grottaglie M; Del Vecchio M; Marubini E; Costa A; Veronesi U
    Tumori; 1996; 82(5):444-9. PubMed ID: 9063520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
    Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
    Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
    Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
    J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.